David A. Roth's most recent trade in Syros Pharmaceuticals Inc. was a trade of 12,099 Common Stock done at an average price of $0.2 . Disclosure was reported to the exchange on Nov. 18, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.20 per share. | 18 Nov 2024 | 12,099 | 0 (0%) | 0% | 0.2 | 2,382 | Common Stock |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 18,875 | 0 | - | - | Restricted Stock Units | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 18,875 | 18,875 (0%) | 0% | - | Common Stock | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 31 Oct 2024 | 6,776 | 12,099 (0%) | 0% | 2.1 | 14,162 | Common Stock |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.95 per share. | 03 Apr 2024 | 10,451 | 0 (0%) | 0% | 4.9 | 51,732 | Common Stock |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 13,333 | 15,333 (0%) | 0% | - | Common Stock | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 13,333 | 26,667 | - | - | Restricted Stock Units | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.12 per share. | 31 Mar 2024 | 4,732 | 10,601 (0%) | 0% | 5.1 | 24,228 | Common Stock |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 2,000 (0%) | 0% | - | Common Stock | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.98 per share. | 31 Mar 2024 | 150 | 10,451 (0%) | 0% | 5.0 | 747 | Common Stock |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.95 per share. | 12 Dec 2023 | 6,287 | 0 (0%) | 0% | 5.0 | 31,121 | Common Stock |
Syros Pharmaceuticals Inc. | A. Roth David | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 06 Dec 2023 | 6,287 | 6,287 (0%) | 0% | 4.0 | 24,834 | Common Stock |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 31 Jul 2023 | 7,348 | 0 (0%) | 0% | 4.0 | 29,025 | Common Stock |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 7,971 (0%) | 0% | - | Common Stock | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 31 Mar 2023 | 623 | 7,348 (0%) | 0% | 2.6 | 1,607 | Common Stock |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 49,750 | 49,750 | - | - | Stock Option (right to buy) | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 37,750 | 37,750 | - | - | Restricted Stock Units | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.12 per share. | 01 Apr 2022 | 27,281 | 59,719 (0%) | 0% | 1.1 | 30,555 | Common Stock |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 200,000 | 200,000 | - | - | Restricted Stock Units | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Restricted Stock Units | |
Syros Pharmaceuticals Inc. | David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 119,000 | 119,000 | - | - | Stock Option (right to buy) |